Tuberculosis News and Research

Latest Tuberculosis News and Research

Migrant access to GPs lacking

Migrants newly arriving in the UK need better access to GPs and primary care services, say experts from the Health Protection Agency.

7 Aug 2012

Children with negative TB skin test at high risk for mortality

Children with clinical signs of tuberculosis but with a negative tuberculin skin test result should not have treatment delayed, suggest study findings showing that false-negatives are common and associated with high mortality.

7 Aug 2012

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

BioDiem recently signed a collaborative agreement with The Royal Melbourne Institute of Technology (RMIT) for the development of non-influenza vaccines using BioDiem’s proprietary live attenuated influenza virus (LAIV) technology.

7 Aug 2012

Generic drugs saved U.S. $1T over 10 years, industry study finds

Generic drug makers released a study Thursday that found generic pharmaceuticals have saved the U.S. -- through private prescriptions as well as Medicare and Medicaid -- more than $1 trillion over 10 years.

3 Aug 2012

Investment in health systems 'a critical prerequisite' in beginning to end AIDS

The XIX International AIDS Conference (AIDS 2012) that took place last week in Washington, D.C., "ignited momentum to shift from 'fighting AIDS' to 'ending AIDS,'" Mohga Kamal-Yanni, senior health adviser at Oxfam International, and Urvarshi Rajcoomer, policy and advocacy adviser at Oxfam in South Africa, write in a Mail & Guardian opinion piece.

3 Aug 2012

Change in drug policy needed to reverse HIV/AIDS epidemic in Eastern Europe, Central Asia

Noting the United Nations last week announced the appointment of Dr. Michel Kazatchkine, the former head of the Global Fund to Fight AIDS, Tuberculosis and Malaria, as the U.N. Secretary-General's new special envoy for HIV/AIDS in Eastern Europe and Central Asia," Kasia Malinowska-Sempruch, director of the Open Society Foundations' global drug policy program, writes in this Huffington Post opinion piece.

3 Aug 2012

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

Pfizer Inc. announced today top-line results from ORAL Start (A3921069), a Phase 3 study of the investigational agent tofacitinib, a novel, oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA).

31 Jul 2012

Advocacy, commitment, investment needed to continue HIV/AIDS response

Some members of Congress "are advocating deep cuts to funding for domestic programs such as the Ryan White CARE Act and international programs such as the Global Fund to Fight AIDS, Tuberculosis and Malaria and PEPFAR," but "what these critics fail to realize is that though we have won a multitude of battles, we are still losing the war in many communities," Rep. Michael Honda (D-Calif.) writes in a U.S. News & World Report opinion piece.

31 Jul 2012

Inclusion of 'marginalized and criminalized' populations essential to HIV/AIDS response

In this post in the Human Rights and HIV/AIDS "Now More Than Ever" blog, Michel Kazatchkine, the former executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria and newly appointed special envoy to U.N. Secretary-General Ban Ki-moon for HIV/AIDS in Eastern Europe and Central Asia, examines why human rights are "so central to the AIDS response."

31 Jul 2012

Limited funding, lack of flexibility forces decisions on how to spend money on disease treatment

Noting "the total clinic-level cost of providing a year's worth of antiretroviral drugs ... ha[s] dropped" in some countries, Charles Kenny, a fellow at the Center for Global Development and the New America Foundation, discusses "disagreement over the effectiveness of the global AIDS response" in this Bloomberg Businessweek opinion piece.

31 Jul 2012

Promising implications for improving cellular immunotherapy for treatment of cancer

New research from the Trudeau Institute laboratory of Dr. Edward L. Pearce (Washington University) has promising implications for improving a treatment for cancer known as cellular immunotherapy. The findings were just published in the The Journal of Immunology.

30 Jul 2012

Early ART treatment delays AIDS-related health events in HIV-infected individuals

Further analyses of the landmark NIH-funded treatment-as-prevention study (HPTN 052) have found that providing antiretroviral treatment to HIV-infected individuals earlier, when their immune systems are healthier, delays AIDS-related health events, such as chronic herpes simplex virus and tuberculosis, as well as death. Additionally, researchers found that earlier HIV treatment is also cost-effective because it increases survival, prevents costly opportunistic infections and averts transmission of the virus to uninfected individuals.

30 Jul 2012

PEPFAR, private partner launch 5-year 'Labs for Life' initiative

At the XIX International AIDS Conference (AIDS 2012) on Thursday, PEPFAR and Becton, Dickinson and Company (BD), "announced Labs for Life, a new collaboration to help strengthen health care and laboratory systems in the developing world along with the U.S. Department of Health and Human Services' Centers for Disease Control and Prevention (CDC)," a State Department fact sheet states.

28 Jul 2012

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

Genentech, a member of the Roche Group, today announced that the BREVACTA study of ACTEMRA (tocilizumab) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its primary endpoint.

28 Jul 2012

NPR continues AIDS-related coverage on blog, programs

NPR continues its coverage of issues being discussed at the XIX International AIDS Conference (AIDS 2012) with several stories on its health blog and radio programs. On Thursday, "Tell Me More" host Michel Martin spoke with Teguest Guerma, the first woman director general of the African Medical and Research Fund (AMREF) about how African nations are responding to the HIV/AIDS epidemic and how they are working "to find the solutions ourselves, with the support of the international community," Guerma said, according to the program's transcript.

28 Jul 2012

Economist articles, blog examine research presented at AIDS 2012 conference

The Economist on Friday published two articles from Saturday's print edition regarding the XIX International AIDS Conference (AIDS 2012). One article states that "few areas of international affairs have seen more recent success than the fight against AIDS," and discusses advancements in HIV treatment research and availability.

28 Jul 2012

Research presented at AIDS 2012 conference renews hope of cure for AIDS

Two studies presented at the XIX International AIDS Conference (AIDS 2012) and one published Wednesday in the British journal Nature "have given researchers renewed hope that a cure for AIDS may be possible," the Washington Post reports.

28 Jul 2012

Recent release: AIDS 2012 session examines possible PEPFAR, Global Fund collaboration

The Center for Global Development's "Global Health Policy" blog reports on a session at the XIX International AIDS Conference (AIDS 2012) examining "how PEPFAR and the Global Fund to Fight AIDS, Tuberculosis and Malaria could collaborate more strategically to maximize impact."

28 Jul 2012

New platform for detecting substandard and counterfeit medicines using microfluidics

A new platform for detecting substandard and counterfeit medicines using microfluidics has been recognized with a grant from Saving Lives at Birth's "Grand Challenge through Development." Dubbed PharmaCheck, the technology is a portable, field-based tool for assessing the quality of medicines in developing countries with increased accuracy, sensitivity and reliability.

27 Jul 2012

TB combination drug: an interview with Mel Spigelman, MD, CEO and President of TB Alliance

TB is a leading global killer. It is the second leading infectious disease in the world, behind HIV. TB is spread through the air, so it can affect anyone, but has its worst impact on impoverished communities and those people with HIV.

27 Jul 2012

Tuberculosis News and Research

Latest Tuberculosis News and Research

Migrant access to GPs lacking

Children with negative TB skin test at high risk for mortality

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

Generic drugs saved U.S. $1T over 10 years, industry study finds

Investment in health systems 'a critical prerequisite' in beginning to end AIDS

Change in drug policy needed to reverse HIV/AIDS epidemic in Eastern Europe, Central Asia

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

Advocacy, commitment, investment needed to continue HIV/AIDS response

Inclusion of 'marginalized and criminalized' populations essential to HIV/AIDS response

Limited funding, lack of flexibility forces decisions on how to spend money on disease treatment

Promising implications for improving cellular immunotherapy for treatment of cancer

Early ART treatment delays AIDS-related health events in HIV-infected individuals

PEPFAR, private partner launch 5-year 'Labs for Life' initiative

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

NPR continues AIDS-related coverage on blog, programs

Economist articles, blog examine research presented at AIDS 2012 conference

Research presented at AIDS 2012 conference renews hope of cure for AIDS

Recent release: AIDS 2012 session examines possible PEPFAR, Global Fund collaboration

New platform for detecting substandard and counterfeit medicines using microfluidics

TB combination drug: an interview with Mel Spigelman, MD, CEO and President of TB Alliance

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Tuberculosis News and Research

Latest Tuberculosis News and Research

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Newsletters you may be interested in